Posted by Michael Wonder on 04 Aug 2022
Lynparza approved in the EU as adjuvant treatment for patients with germline BRCA mutated HER2 negative high-risk early breast cancer
4 August 2022 - First and only approved medicine targeting BRCA mutations in early breast cancer
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations, who have HER2 negative high-risk early breast cancer previously treated with neo-adjuvant or adjuvant chemotherapy.
